Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of α/β Biased IL-2, STK-012, for Treatment of Advanced Solid Tumors Portfolio News / By Karina Tin April 9, 2024 Synthekine Presents Positive Initial Results from Phase 1a/1b Clinical Trial of α/β Biased IL-2, STK-012, for Treatment of Advanced Solid Tumors Read More »
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies Portfolio News / By Karina Tin April 9, 2024 Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies Read More »
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6 Portfolio News / By Karina Tin April 9, 2024 Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6 Read More »
Accent Therapeutics Presents Data Supporting Two Lead Programs at AACR 2024 Annual Meeting Portfolio News / By Karina Tin April 8, 2024 Accent Therapeutics Presents Data Supporting Two Lead Programs at AACR 2024 Annual Meeting Read More »
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting Portfolio News / By Karina Tin April 8, 2024 ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting Read More »
NGM Bio Announces Closing of Tender Offer Portfolio News / By Karina Tin April 5, 2024 NGM Bio Announces Closing of Tender Offer Read More »
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences Portfolio News / By Karina Tin April 2, 2024 Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences Read More »
Synthekine Announces U.S. FDA Clearance of IND Application for CD19 CAR-T and Orthogonal IL-2 Combination Therapy, SYNCAR-001 + STK-009, for Treatment of Lupus Without Lymphodepletion Portfolio News / By Karina Tin March 26, 2024 Synthekine Announces U.S. FDA Clearance of IND Application for CD19 CAR-T and Orthogonal IL-2 Combination Therapy, SYNCAR-001 + STK-009, for Treatment of Lupus Without Lymphodepletion Read More »
A2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directors Portfolio News / By Karina Tin March 25, 2024 A2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directors Read More »
Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD) Portfolio News / By Karina Tin March 25, 2024 Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD) Read More »
